Why bluebird bio Failed: Unit Economics | Startup Autopsy
$4.0B
Raised
14y
Time to collapse
$10.0B
Peak valuation
// startup autopsy
bluebird bio
The gene therapy pioneer that spent 14 years and 4B dollars developing cures for rare diseases and became a zombie when payers refused to cover the 2.8M dollar price tag.
Evaluating only bluebird bio’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. That’s exactly how it died.
Key Events Timeline
FOUNDING
bluebird bio founded
DOWN ROUND
Down round or bridge financing
SHUTDOWN
Zombie Startup: bluebird bio ceases operations
Full Analysis
Free · no account needed
Documented cause
bluebird bio developed gene therapies for sickle cell disease (Lyfgenia, $3.1M) and beta-thalassemia (Zynteglo, $2.8M). FDA approved both. But commercial launch was catastrophic: payers refused reimbursement at those prices. The company sold its European operations and laid off 30% in 2022. Revenue never met projections. Stock fell 95%+ from peak. Near-zombie status by 2024.
Lesson
“One-time gene therapy pricing models require outcomes-based reimbursement agreements with payers before FDA approval. No US payer is structured to absorb a single $3M payment; the installment reimbursement infrastructure does not exist yet.”